Vertex Pharmaceuticals (VRTX)
Develops cystic fibrosis medicines, gene-edited cell therapy, and non-opioid pain treatment.
$515.31
After hours+0.19 (+0.04%)
At close$515.12(+0.86%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2,484 | 2,518 | 2,687 | 2,646 | 2,772 | 2,912 | 2,770 | 2,965 | 3,076 | 3,227 | 2,987 | 3,334 |
| Cost of revenue | 319 | 368 | 343 | 372 | 393 | 423 | 363 | 408 | 415 | 466 | 393 | 489 |
| Gross profit | 2,165 | 2,150 | 2,345 | 2,274 | 2,379 | 2,489 | 2,407 | 2,557 | 2,662 | 2,761 | 2,594 | 2,845 |
| 1,126 | 1,161 | 1,209 | 5,788 | 1,263 | 1,463 | 1,777 | 1,406 | 1,475 | 1,461 | 1,456 | 1,598 | |
| Research & development | 862 | 1,352 | 866 | 5,416 | 876 | 999 | 980 | 978 | 1,032 | 974 | 962 | 994 |
| Selling, general & administrative | 264 | 369 | 343 | 372 | 372 | 378 | 396 | 425 | 445 | 487 | 494 | 582 |
| Other expenses | 0 | −560 | 0 | 1 | 15 | 86 | 401 | 3 | −2 | 0 | 1 | 22 |
| Operating income | 1,038 | 989 | 1,140 | −3,515 | 1,116 | 1,026 | 630 | 1,151 | 1,186 | 1,300 | 1,138 | 1,247 |
| 141 | 159 | 140 | 124 | 108 | 111 | 100 | 132 | 113 | 31 | 115 | 145 | |
| Interest income | 168 | 180 | 181 | 157 | 132 | 128 | 121 | 122 | 126 | 122 | 115 | 121 |
| Interest expense | 11 | 11 | 10 | 10 | 8 | 3 | 3 | 4 | 3 | 3 | 0 | 0 |
| Other non-operating income | −152 | −170 | −150 | −133 | −115 | −113 | −103 | −136 | −116 | −34 | −115 | −145 |
| Income before tax | 1,179 | 1,148 | 1,279 | −3,391 | 1,224 | 1,137 | 730 | 1,283 | 1,299 | 1,331 | 1,253 | 1,392 |
| Income tax expense | 144 | 179 | 180 | 202 | 179 | 224 | 84 | 250 | 216 | 140 | 222 | 292 |
| Net income from continuing operations | 1,035 | 969 | 1,100 | −3,594 | 1,045 | 913 | 646 | 1,033 | 1,083 | 1,191 | 1,031 | 1,100 |
| Net income | 1,035 | 969 | 1,100 | −3,594 | 1,045 | 913 | 646 | 1,033 | 1,083 | 1,191 | 1,031 | 1,100 |
| EPS, basic | $4.01 | $3.76 | $4.26 | −$13.92 | $4.05 | $3.55 | $2.52 | $4.02 | $4.24 | $4.69 | $4.06 | $4.33 |
| EPS, diluted | $3.97 | $3.71 | $4.21 | −$13.92 | $4.01 | $3.50 | $2.49 | $3.99 | $4.20 | $4.65 | $4.02 | $4.31 |
| Weighted average shares, basic | 258 | 258 | 258 | 258 | 258 | 258 | 257 | 257 | 256 | 254 | 254 | 254 |
| Weighted average shares, diluted | 261 | 261 | 261 | 258 | 261 | 261 | 260 | 259 | 258 | 256 | 256 | 256 |
| EBITDA | 1,232 | 1,217 | 1,343 | −3,327 | 1,285 | 1,184 | 782 | 1,338 | 1,356 | 1,387 | 1,309 | 1,392 |
| Depreciation & amortization | 42 | 59 | 54 | 54 | 53 | 47 | 48 | 52 | 54 | 53 | 56 | 0 |
| EBIT | 1,190 | 1,158 | 1,290 | −3,381 | 1,232 | 1,139 | 733 | 1,287 | 1,302 | 1,334 | 1,253 | 1,392 |